Inventor · disambiguated record
Manuel Sepulveda
Also filed as: SEPULVEDA MANUEL · SEPULVEDA MANUEL ALEJANDRO
16 granted patents·14 pending applications·56 citations·filing 2013–2025
91Inventor score
Top patents by PatentIndex Score
30 records- 0195US12188938B2Anti-VISTA antibodies and fragmentsJANSSEN PHARMACEUTICA NV·Filed 2021·Granted Jan 7, 2025·4 cites·18 claims
- 0295US11299534B2CD8A-binding fibronectin type III domainsJANSSEN BIOTECH INC·Filed 2020·Granted Apr 12, 2022·4 cites·20 claims
- 0395US10626165B2CD8a-binding fibronectin type III domainsJANSSEN BIOTECH INC·Filed 2017·Granted Apr 21, 2020·14 cites·19 claims
- 0494US11932680B2CD8A-binding fibronectin type III domainsJANSSEN BIOTECH INC·Filed 2022·Granted Mar 19, 2024·2 cites·4 claims
- 0594US10597438B2PD-L1 binding fibronectin type III domainsJANSSEN BIOTECH INC·Filed 2017·Granted Mar 24, 2020·12 cites·17 claims
- 0693US11009509B2Anti-VISTA antibodies and fragmentsJANSSEN PHARMACEUTICA NV·Filed 2016·Granted May 18, 2021·7 cites·26 claims
- 0791US10611823B2CD137 binding fibronectin type III domainsJANSSEN BIOTECH INC·Filed 2017·Granted Apr 7, 2020·12 cites·11 claims
- 0884US2025354994A1Anti-vista antibodies and fragmentsJANSSEN PHARMACEUTICA NV·Filed 2024·Application pending·0 cites
- 0982US11345739B2CD137 binding fibronectin type III domainsJANSSEN BIOTECH INC·Filed 2020·Granted May 31, 2022·1 cites·20 claims
- 1078US12258385B2CD137 binding fibronectin type III domainsJANSSEN BIOTECH INC·Filed 2022·Granted Mar 25, 2025·0 cites·9 claims
- 1168US2024294884A1Vaccines based on mutant calr and jak2 and their usesJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 1268US2024254161A1Neoantigens Expressed In Ovarian Cancer And Their UsesJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 1364US12264197B2Anti-Vβ17/anti-CD123 bispecific antibodiesJANSSEN BIOTECH INC·Filed 2020·Granted Apr 1, 2025·0 cites·25 claims
- 1464US11447539B2PD-L1 binding fibronectin type III domainsJANSSEN BIOTECH INC·Filed 2020·Granted Sep 20, 2022·0 cites·13 claims
- 1564US2024269203A1Oncolytic virus and uses thereofJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 1662US2025257132A1ANTI-Vbeta17/ANTI-CD123 BISPECIFIC ANTIBODIESJANSSEN BIOTECH INC·Filed 2025·Application pending·0 cites
- 1761US12295997B2Prostate neoantigens and their usesJANSSEN BIOTECH INC·Filed 2021·Granted May 13, 2025·0 cites·31 claims
- 1859US12018289B2Vaccines based on mutant CALR and JAK2 and their usesJANSSEN BIOTECH INC·Filed 2020·Granted Jun 25, 2024·0 cites·26 claims
- 1957US11945881B2Neoantigens expressed in ovarian cancer and their usesJANSSEN BIOTECH INC·Filed 2021·Granted Apr 2, 2024·0 cites·21 claims
- 2054US11793843B2Prostate neoantigens and their usesJANSSEN BIOTECH INC·Filed 2020·Granted Oct 24, 2023·0 cites·29 claims
- 2154US2023285548A1Vaccines based on mutant calr and jak2 and their usesJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 2254US2023190903A1Prostate cancer vaccines and uses thereofJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 2353US12275766B2Neoantigen peptide mimicsJANSSEN BIOTECH INC·Filed 2021·Granted Apr 15, 2025·0 cites·14 claims
- 2453US2021315986A1Psma and steap1 vaccines and their usesJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 2552US2024166720A1Bioengineered immunomodulatory fusion protein compositionsJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 2652US2023024133A1Prostate Neoantigens And Their UsesJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 2751US2015065007A1Magnetic building blocksCUBECRAFT LLC·Filed 2013·Application pending·0 cites
- 2850US2021261636A1Neoantigens expressed in multiple myeloma and their usesJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 2949US2023079750A1Calr and jak2 t-cell receptorsJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 3048US2023035403A1Method For Determining Responsiveness To Prostate Cancer TreatmentJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Manuel Sepulveda files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →